Corpus overview


MeSH Disease

HGNC Genes

There are no HGNC terms in the subcorpus

SARS-CoV-2 proteins

ProteinN (2)

ProteinS (1)


SARS-CoV-2 Proteins
    displaying 1 - 2 records in total 2
    records per page

    Estimates of the rate of infection and asymptomatic COVID-19 MESHD disease in a population sample from SE England

    Authors: Philippa M Wells; Katie M Doores; Simon Couvreur; Rocio Martin Martinez; Jeffrey Seow; Carl Graham; Sam Acors; Neophytos Kouphou; Stuart Neil; Richard Tedder; Pedro Matos; Kate Poulton; Maria Jose Lista; Ruth Dickenson; Helin Sertkaya; Thomas Maguire; Edward Scourfield; Ruth Bowyer; Deborah Hart; Aoife O'Byrne; Kathryn Steele; Oliver Hemmings; Carolina Rosadas; Myra McClure; Joan Capedevila-Pujol; Jonathan wolf; Sebastien Ourseilin; Matthew Brown; Michael Malim; Timothy Spector; Claire Steves

    doi:10.1101/2020.07.29.20162701 Date: 2020-07-30 Source: medRxiv

    Background: Understanding of the true asymptomatic rate of infection of SARS-CoV-2 MESHD is currently limited, as is understanding of the population-based seroprevalence after the first wave of COVID-19 MESHD within the UK. The majority of data thus far come from hospitalised patients, with little focus on general population cases, or their symptoms. Methods: We undertook enzyme linked immunosorbent assay characterisation of IgM and IgG responses against SARS-CoV-2 spike PROTEIN glycoprotein and nucleocapsid protein PROTEIN of 431 unselected general-population participants of the TwinsUK cohort from South-East England, aged 19-86 (median age 48; 85% female). 382 participants completed prospective logging of 14 COVID-19 MESHD related symptoms via the COVID Symptom Study App, allowing consideration of serology alongside individual symptoms, and a predictive algorithm for estimated COVID-19 MESHD previously modelled on PCR positive individuals from a dataset of over 2 million. Findings: We demonstrated a seroprevalence of 12% (51participants of 431). Of 48 seropositive individuals with full symptom data, nine (19%) were fully asymptomatic, and 16 (27%) were asymptomatic for core COVID-19 MESHD symptoms: fever MESHD, cough MESHD or anosmia MESHD. Specificity of anosmia MESHD for seropositivity was 95%, compared to 88% for fever cough MESHD and anosmia MESHD combined. 34 individuals in the cohort were predicted to be Covid-19 MESHD positive using the App algorithm, and of those, 18 (52%) were seropositive. Interpretation: Seroprevalence amongst adults from London and South-East England was 12%, and 19% of seropositive individuals with prospective symptom logging were fully asymptomatic throughout the study. Anosmia demonstrated the highest symptom specificity for SARS-CoV-2 antibody response. Funding: NIHR BRC, CDRF, ZOE global LTD, RST-UKRI/MRC

    Cancer Patient Management Strategy in a Cancer Center of Zhejiang, China During the COVID-19 Pandemic MESHD 

    Authors: Song-xiao Xu; Xiang-dong Cheng; Zhi-wen Pan; Qian Song; Yi-hong Wang; Juan Xiong; Yong-yi Chen; Fan Fan; Jing Zhu; Wan-ying Wu; Xue-ying Deng; Yan-pin Yu; Xiao-hong Xu; Wen-hu Chen; Tao Zhu; Yang Yu; Kai-zhong Liu; Guo-liang Shao; Ming Chen; En-yan Yu

    doi:10.21203/ Date: 2020-05-19 Source: ResearchSquare

    Background: Due to the increased risk of v iral infection MESHDand the severe shortage of medical resources during the pandemic of COVID-19 MESHD, most hospitals in the epidemic areas significantly reduced non-emergency admissions and services, if not closed. As a result, it has been difficult to treat c ancer MESHDpatients on time, which adversely affects their prognosis. To address this problem, c ancer MESHDcenters must develop a strategic plan to manage both inpatients and outpatients during the pandemic, provide them with the necessary treatment, and at the same time prevent the spread of the virus among patients, visitors and medical staff. Methods: Based upon the epidemic situation in Zhejiang Province, China, the number of running non-emergency medical wards in the Zhejiang Cancer Hospital was gradually increased in a controlled manner. All staff of the hospital received COVID-19 MESHD preventive training and was provided with three different levels of protection according to the risks of their services. Only patients without a known history of SARS-CoV-2 contact were eligible to schedule an appointment. Body temperature was measured on all patients upon their arrival at the hospital. Chest CT image, blood cell counting and travel/contact history were investigated in patients with f ever. MESHD Respiratory tract samples, such as sputum and throat swabs, from all patients, including those clinically suspected of SARS-CoV-2 infection MESHD ARS-CoV-2 infection, MESHD were collected for nucleic acid detection of SARS-CoV-2 before treatment.Results: A total of 3697 inpatients and 416 outpatients seeking c ancer MESHDtreatment were enrolled from February 1 to April 3, 2020, in compliance with the hospital’s infection-control interventions. The clinicopathological parameters of the patients were summarized herein. 4237 samples from 4101 patients produced negative RNA testing results. Four clinically suspected patients all presented negative RNA test results and were excluded from the SARS-CoV-2 infection MESHD ARS-CoV-2 infection MESHDthrough follow-up retesting and monitoring. Seven patients with only N-gene PROTEIN positive results were retested, followed by CT scan and SARS-CoV-2 contact history investigation. All of them were finally diagnosed as n on-infected MESHDpatients. There was one outpatient who was confirmed positive by virus RNA test and then followed up. She might be an asymptomatic laboratory-confirmed case. During the study period, there was no SARS-CoV-2 infection MESHD ARS-CoV-2 infection MESHDamong staff, patients and escorts of patients in the Zhejiang Cancer Hospital.Conclusion: This study suggested our infection-control interventions, including viral nucleic acid test, could be used as a reliable method to screen c ancer MESHDpatients in the area with moderate COVID-19 MESHD prevalence. C ancer MESHDmay not be a high-risk factor of SARS-CoV-2 infection MESHD ARS-CoV-2 infection. MESHD 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.